HIV Citations List: April 2025
Literature Citations
1. Inhibition of ALKBH5 Demethylase of m(6)a Pathway Potentiates HIV-1 Reactivation from Latency. Ali, H., J. Wadas, M. Bendoumou, H.C. Chen, P. Maiuri, A. Dutilleul, S. Selberg, L. Nestola, K. Lalik, V. Avettand-Fenoël, C. Necsoi, A. Marcello, E. Kankuri, M. Karelson, S. De Wit, K. Pyrc, A.O. Pasternak, C. Van Lint, and A. Kula-Pacurar. Virology Journal, 2025. 22(1): p. 124. PMID[40296171]. PMCID[PMC12039216].
[PubMed]. HIV_04_2025.
2. HIV-1 Gag-Protease-Driven Replicative Capacity Influences T-Cell Metabolism, Cytokine Induction, and Viral Cell-to-Cell Spread. Baiyegunhi, O.O., K. Mthembu, A.K. Reuschl, D. Ojwach, O. Farinre, M. Maimela, S. Balinda, M. Price, M.J. Bunders, M. Altfeld, C. Jolly, J. Mann, and T. Ndung'u. mBio, 2025. 16(4): p. e0356524. PMID[39998252]. PMCID[PMC11980368].
[PubMed]. HIV_04_2025.
3. A gp41 HR2 Residue Modulates the Susceptibility of HIV-1 Envelope Glycoproteins to Small Molecule Inhibitors Targeting gp120. Chatterjee, D., L. Niu, H. Medjahed, S. Ding, M. Benlarbi, É. Bélanger, J. Prévost, H.C. Chen, W.D. Tolbert, A.B. Smith, 3rd, M. Pazgier, and A. Finzi. Journal of Virology, 2025. 99(4): p. e0226724. PMID[40145736]. PMCID[PMC11998491].
[PubMed]. HIV_04_2025.
4. Forsythoside B Activates Siglec-14 to Inhibit HIV-1 Replication Via the JAK1/STAT1 Pathway. Chen, S., X. Hu, F. Chen, J. Liu, J. Su, R. Chen, W. Wei, Z. Yuan, S. An, L. Ye, H. Liang, and J. Jiang. International Journal of Biological Macromolecules, 2025. 303: p. 140632. PMID[39909240].
[PubMed]. HIV_04_2025.
5. Assessing Phenotypic Effect of Integrase Strand-Transfer Inhibitor (INSTI)-Based Resistance Substitutions Associated with Failures on Cabotegravir. D'Antoni, M.L., B. Falkard, K. Andreatta, S. Cox, C. Cohen, and C. Callebaut. Journal of Antimicrobial Chemotherapy, 2025. 80(4): p. 962-966. PMID[39849846]. PMCID[PMC11962372].
[PubMed]. HIV_04_2025.
6. New Imidazo 2,1-b Thiazole Linked Hydrazide-Hydrazones as Potent a-Glucosidase Inhibitors: Synthesis, Biological Evaluation, and Docking Insights. Durmaz, N., F. Basoglu, E.D. Dincel, G. Hasbal-Celikok, M. Camci, T. Yilmaz-Ozden, and N. Ulusoy-Güzeldemirci. ChemistrySelect, 2025. 10(15). ISI[001466942000001].
[WOS]. HIV_04_2025.
7. Spatiotemporal Binding of Cyclophilin A and CPSF6 to Capsid Regulates HIV-1 Nuclear Entry and Integration. Ingram, Z., C. Kline, A.K. Hughson, P.K. Singh, H.L. Fischer, R. Radhakrishnan, G.A. Sowd, N.F.B. Dos Santos, B.K. Ganser-Pornillos, S.C. Watkins, M. Kane, A.N. Engelman, and Z. Ambrose. mBio, 2025. 16(4): p. e0016925. PMID[40013779]. PMCID[PMC11980554].
[PubMed]. HIV_04_2025.
8. Myosin IXB Protects Immune Cells from Virus Infection. Kogachi, L., T. Matozo, Y.T. Magalhães, M. Janoni Bayerlein, T.C. Braga, F.E.C. Camargo, S.S.K.B. da, F.L. Forti, and B.C. de Alencar. Journal of General Virology, 2025. 106(4). PMID[40167026]. PMCID[PMC11962068].
[PubMed]. HIV_04_2025.
9. Lenacapavir Disrupts HIV-1 Core Integrity While Stabilizing the Capsid Lattice. Li, C., R.C. Burdick, R. Siddiqui, S.K. Janaka, R.C. Hsia, W.S. Hu, and V.K. Pathak. Proceedings of the National Academy of Sciences of the United States of America, 2025. 122(14): p. e2420497122. PMID[40168125]. PMCID[PMC12002175].
[PubMed]. HIV_04_2025.
10. PD-1 Suppression Enhances HIV Reactivation and T-Cell Immunity Via MAPK/NF-ΚB Signaling. Lin, X., B. Song, L. Cao, L. Zhang, S. Liu, X. Wang, X. Chen, and S. Li. European Journal of Medical Research, 2025. 30(1): p. 237. PMID[40186291]. PMCID[PMC11969704].
[PubMed]. HIV_04_2025.
11. Engineering of CD8(+) T Cells with an HIV-Specific Synthetic Notch Receptor to Secrete Broadly Therapeutic Antibodies for Combining Antiviral Humoral and Cellular Immune Responses. Meng, L., H. Zhao, S. Chang, W. Li, Y. Tian, R. Wang, L. Wang, T. Gu, J. Wu, B. Yu, C. Wang, and X. Yu. mBio, 2025. 16(4): p. e0383924. PMID[39998238]. PMCID[PMC11980546].
[PubMed]. HIV_04_2025.
12. Heat Shock Protein 90 Is a Chaperone Regulator of HIV-1 Latency. Noorsaeed, S., N. AlBurtamani, A. Rokan, and A. Fassati. PLoS Pathogens, 2025. 21(4): p. e1012524. PMID[40168429]. PMCID[PMC11981193].
[PubMed]. HIV_04_2025.
13. The Ectodomain Sheddase ADAM10 Restricts HIV-1 Propagation and Is Counteracted by Nef. Olety, B., Y. Usami, P. Peters, Y. Wu, and H. Göttlinger. Science Advances, 2025. 11(16): p. eadt1836. PMID[40249826]. PMCID[PMC12007588].
[PubMed]. HIV_04_2025.
14. Anti-HIV Diterpenoids from Daphne Pseudomezereum. Otsuki, K., C. Hosoya, R. Takamiya, M. Kimura, T. Kikuchi, L. Huang, C.H. Chen, and W. Li. Phytochemistry, 2025. 232: p. 114366. PMID[39694394]. PMCID[PMC11748344].
[PubMed]. HIV_04_2025.
15. Pharmacological Characterization of a Clinical Candidate, TG-0054, a Small Molecule Inverse Agonist Targeting CXCR4. Pan, K.S., Z. Wang, C. Pfeil, N.D. Bergkamp, S. Mobach, S. Roth, A. Rizk, M.J. Lohse, P. Annibale, M. Siderius, M. Zimmermann, M.J. Smit, and R. Bosma. Molecular Pharmacology, 2025. 107(4): p. 100015. PMID[40156952].
[PubMed]. HIV_04_2025.
16. GS143, an Inhibitor of E3 Ligase Β-TrCP, Reverses HIV-1 Latency without Activating T Cells Via Unconventional Activation of NFκB. Sarkar, S., Y. Kobayashi, T. Russnak, J. Shen, R.G. Nahass, J.P. Dougherty, and C. Gélinas. PLoS Pathogens, 2025. 21(4): p. e1013018. PMID[40168443]. PMCID[PMC11999137].
[PubMed]. HIV_04_2025.
17. Design and Characterization of Inhibitors of Cell-Mediated Degradation of APOBEC3G That Decrease HIV-1 Infectivity. Sawyer, A.M., C.C. Vaca, N. Malik, I. Clerc, J. Craft, H. Hudson, G.K. Scholtés, G.E. Schiltz, M. Roh, C. Song, and R.T. D'Aquila. Viruses, 2025. 17(4). PMID[40284957]. PMCID[PMC12031279].
[PubMed]. HIV_04_2025.
18. Bet Degraders Reveal BRD4 Disruption of 7SK and P-TEFb Is Critical for Effective Reactivation of Latent HIV in CD4+ T-Cells. Turner, A.M., F.M. Bashore, S.D. Falcinelli, J.A. Fox, A.L. Keller, A.D. Fenton, R.F. Geyer, B. Allard, J.L. Kirchherr, N.M. Archin, L.I. James, and D.M. Margolis. Journal of Virology, 2025. 99(4): p. e0177724. PMID[40067013]. PMCID[PMC11998493].
[PubMed]. HIV_04_2025.
19. Addition of a Short HIV-1 Fusion-Inhibitory Peptide to Pro 140 Antibody Dramatically Increases Its Antiviral Breadth and Potency. Yan, H., Y. Gao, Y. Zhu, H. Chong, Y. Gong, Y. Chen, L. Li, B. Su, and Y. He. Journal of Virology, 2025. 99(4): p. e0201824. PMID[40130879]. PMCID[PMC11998511].
[PubMed]. HIV_04_2025.
20. ReaxFF-Guided Optimization of VIRIP-Based HIV-1 Entry Inhibitors. Zech, F., C. Jung, A.A. Rodríguez Alfonso, J. Köhler, L. Ständker, G. Weidinger, T. Jacob, and F. Kirchhoff. The Journal of Physical Chemistry B, 2025. 129(15): p. 3788-3795. PMID[40178988]. PMCID[PMC12010322].
[PubMed]. HIV_04_2025.
Patent Citations
21. Preparation of bridged tricyclic carbamoylpyridone compounds and uses thereof for treatment of HIV infection. Armstrong, M.K., C. Chou, M.O. Clarke, A.Z. Gonazalez Buenrostro, X. Han, L. Jiang, J. Li, G.M. Schwarzwalder, Q. Wu, and H. Yang. Patent. 2025. WO2024-US507962025080850: 384 pp.
[Patent]. HIV_04_2025.
22. Preparation of bridged tricyclic carbamoylpyridone compounds and uses thereof for treatment of HIV infection. Armstrong, M.K., C. Chou, A.Z. Gonazalez Buenrostro, X. Han, L. Jiang, J. Li, M.L. Mitchell, G.M. Schwarzwalder, A.B. Shodeinde, M. Subrammanian, Q. Wu, and H. Yang. Patent. 2025. WO2024-US508322025080879: 341 pp.
[Patent]. HIV_04_2025.
23. Preparation of bridged tricyclic carbamoylpyridone compounds and uses thereof for treatment of HIV infection. Armstrong, M.K., C. Chou, A.Z. Gonazalez Buenrostro, X. Han, L. Jiang, J. Li, G.M. Schwarzwalder, Q. Wu, and H. Yang. Patent. 2025. WO2024-US508122025080863: 328 pp.
[Patent]. HIV_04_2025.